434 related articles for article (PubMed ID: 32007707)
1. CTLA-4: From mechanism to autoimmune therapy.
Hosseini A; Gharibi T; Marofi F; Babaloo Z; Baradaran B
Int Immunopharmacol; 2020 Mar; 80():106221. PubMed ID: 32007707
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of CTLA-4-Ig in tolerance induction.
Alegre ML; Fallarino F
Curr Pharm Des; 2006; 12(2):149-60. PubMed ID: 16454732
[TBL] [Abstract][Full Text] [Related]
3. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.
Fife BT; Bluestone JA
Immunol Rev; 2008 Aug; 224():166-82. PubMed ID: 18759926
[TBL] [Abstract][Full Text] [Related]
4. CTLA-4 and T cell activation.
Oosterwegel MA; Greenwald RJ; Mandelbrot DA; Lorsbach RB; Sharpe AH
Curr Opin Immunol; 1999 Jun; 11(3):294-300. PubMed ID: 10375557
[TBL] [Abstract][Full Text] [Related]
5. B lymphocyte alterations accompany abatacept resistance in new-onset type 1 diabetes.
Linsley PS; Greenbaum CJ; Speake C; Long SA; Dufort MJ
JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830871
[TBL] [Abstract][Full Text] [Related]
6. The CD28-B7 costimulatory pathway and its role in autoimmune disease.
Daikh D; Wofsy D; Imboden JB
J Leukoc Biol; 1997 Aug; 62(2):156-62. PubMed ID: 9261329
[TBL] [Abstract][Full Text] [Related]
7. T cells of staphylococcal enterotoxin B-tolerized autoimmune MRL-lpr/lpr mice require co-stimulation through the B7-CD28/CTLA-4 pathway for activation and can be reanergized in vivo by stimulation of the T cell receptor in the absence of this co-stimulatory signal.
Zhou T; Weaver C; Linsley PS; Mountz JD
Eur J Immunol; 1994 May; 24(5):1019-25. PubMed ID: 7514125
[TBL] [Abstract][Full Text] [Related]
8. CTLA-4 and autoimmunity: new insights into the dual regulator of tolerance.
Romo-Tena J; Gómez-Martín D; Alcocer-Varela J
Autoimmun Rev; 2013 Oct; 12(12):1171-6. PubMed ID: 23851140
[TBL] [Abstract][Full Text] [Related]
9. Targeting Costimulatory Pathways in Systemic Sclerosis.
Boleto G; Allanore Y; Avouac J
Front Immunol; 2018; 9():2998. PubMed ID: 30619351
[TBL] [Abstract][Full Text] [Related]
10. CTLA-4Ig: uses and future directions.
Ben-Shoshan M
Recent Pat Inflamm Allergy Drug Discov; 2009 Jun; 3(2):132-42. PubMed ID: 19519590
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapies: the blockade of inhibitory signals.
Wu YL; Liang J; Zhang W; Tanaka Y; Sugiyama H
Int J Biol Sci; 2012; 8(10):1420-30. PubMed ID: 23197939
[TBL] [Abstract][Full Text] [Related]
12. T-cell co-stimulation by CD28-CD80/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development.
Ewing MM; Karper JC; Abdul S; de Jong RC; Peters HA; de Vries MR; Redeker A; Kuiper J; Toes RE; Arens R; Jukema JW; Quax PH
Int J Cardiol; 2013 Oct; 168(3):1965-74. PubMed ID: 23351788
[TBL] [Abstract][Full Text] [Related]
13. Targeting T cell costimulation in autoimmune disease.
Stuart RW; Racke MK
Expert Opin Ther Targets; 2002 Jun; 6(3):275-89. PubMed ID: 12223069
[TBL] [Abstract][Full Text] [Related]
14. Coinhibitory molecules in autoimmune diseases.
Watanabe N; Nakajima H
Clin Dev Immunol; 2012; 2012():269756. PubMed ID: 22997525
[TBL] [Abstract][Full Text] [Related]
15. CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression.
Carreno BM; Bennett F; Chau TA; Ling V; Luxenberg D; Jussif J; Baroja ML; Madrenas J
J Immunol; 2000 Aug; 165(3):1352-6. PubMed ID: 10903737
[TBL] [Abstract][Full Text] [Related]
16. CTLA-4: a key regulatory point in the control of autoimmune disease.
Scalapino KJ; Daikh DI
Immunol Rev; 2008 Jun; 223():143-55. PubMed ID: 18613834
[TBL] [Abstract][Full Text] [Related]
17. Role of the B7-CD28/CTLA-4 pathway in autoimmune disease.
Chang TT; Kuchroo VK; Sharpe AH
Curr Dir Autoimmun; 2002; 5():113-30. PubMed ID: 11826754
[No Abstract] [Full Text] [Related]
18. [Manipulation of costimulatory pathways in autoimmune disease].
Kaneko H; Nakajima A; Azuma M
Nihon Rinsho; 1997 Jun; 55(6):1531-6. PubMed ID: 9200944
[TBL] [Abstract][Full Text] [Related]
19. Beyond T-Cells: Functional Characterization of CTLA-4 Expression in Immune and Non-Immune Cell Types.
Oyewole-Said D; Konduri V; Vazquez-Perez J; Weldon SA; Levitt JM; Decker WK
Front Immunol; 2020; 11():608024. PubMed ID: 33384695
[TBL] [Abstract][Full Text] [Related]
20. Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig.
Knoerzer DB; Karr RW; Schwartz BD; Mengle-Gaw LJ
J Clin Invest; 1995 Aug; 96(2):987-93. PubMed ID: 7543497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
